Vmbook Online ordering

Versartis Inc

Versartis, Inc. (VSAR) is a biopharmaceutical company that focused on the development and commercialization of therapies for growth hormone deficiency (GHD). The company's lead product candidate, Somatropin (recombinant) for injection, was a long-acting form of recombinant human growth hormone (rhGH) for the treatment of GHD in children and adolescents.

Historically, Versartis was founded in 2009 and headquartered in Redwood City, California. The company went public in 2014 and its stock (VSAR) was listed on NASDAQ stock exchange.

However, in terms of recent news, on September 20, 2019, Versartis announced that it will be acquired by pharmaceutical company, Ascendis Pharma A/S, in an all-stock transaction. As a result, Versartis has ceased its operations as a separate, stand-alone entity, and the VSAR stock has been delisted from NASDAQ as of October 31, 2019.

Therefore, it is not possible to provide information on Versartis's current earnings, growth, or other financial metrics. However, please note that the acquisition by Ascendis Pharma may provide new opportunities for Versartis's product candidates and technology in the future, and interested investors should follow the progress of Ascendis Pharma for further updates.